GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Cyclically Adjusted PS Ratio

Swedish Orphan Biovitrum AB (LTS:0MTD) Cyclically Adjusted PS Ratio : 6.24 (As of May. 31, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio?

As of today (2024-05-31), Swedish Orphan Biovitrum AB's current share price is kr282.70. Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr45.30. Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio for today is 6.24.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0MTD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.89   Med: 7.73   Max: 21.25
Current: 6.24

During the past years, Swedish Orphan Biovitrum AB's highest Cyclically Adjusted PS Ratio was 21.25. The lowest was 4.89. And the median was 7.73.

LTS:0MTD's Cyclically Adjusted PS Ratio is ranked worse than
86.69% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.085 vs LTS:0MTD: 6.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted revenue per share data for the three months ended in Mar. 2024 was kr18.183. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr45.30 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.21 7.22 6.53 5.74 6.17

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 5.09 5.43 6.17 5.95

Competitive Comparison of Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio falls into.



Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=282.70/45.3
=6.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Swedish Orphan Biovitrum AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=18.183/132.2054*132.2054
=18.183

Current CPI (Mar. 2024) = 132.2054.

Swedish Orphan Biovitrum AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.383 100.432 3.137
201409 2.390 100.161 3.155
201412 2.522 100.225 3.327
201503 3.096 99.950 4.095
201506 2.732 99.995 3.612
201509 2.806 100.228 3.701
201512 2.905 100.276 3.830
201603 4.511 100.751 5.919
201606 5.213 101.019 6.822
201609 4.157 101.138 5.434
201612 4.584 102.022 5.940
201703 4.944 102.022 6.407
201706 5.796 102.752 7.457
201709 5.665 103.279 7.252
201712 6.621 103.793 8.433
201803 6.939 103.962 8.824
201806 8.074 104.875 10.178
201809 8.171 105.679 10.222
201812 9.078 105.912 11.332
201903 10.781 105.886 13.461
201906 10.224 106.742 12.663
201909 9.458 107.214 11.663
201912 15.762 107.766 19.337
202003 14.913 106.563 18.502
202006 9.873 107.498 12.142
202009 9.537 107.635 11.714
202012 14.626 108.296 17.855
202103 11.706 108.360 14.282
202106 10.361 108.928 12.575
202109 12.110 110.338 14.510
202112 15.713 112.486 18.468
202203 15.814 114.825 18.208
202206 12.425 118.384 13.876
202209 12.589 122.296 13.609
202212 19.428 126.365 20.326
202303 16.717 127.042 17.396
202306 15.521 129.407 15.857
202309 16.211 130.224 16.458
202312 19.089 131.912 19.131
202403 18.183 132.205 18.183

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Swedish Orphan Biovitrum AB  (LTS:0MTD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines